Company:  SIGA TECHNOLOGIES INC (SIGA)
Form Type:  10-K
Filing Date:  3/10/2014 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
 
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.34  
Change: 
-0.0497 (-3.58%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$71.70M
Description of Business
Since we were incorporated in Delaware on December 28, 1995, SIGA has pursued the research, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents such as smallpox and Arenaviruses. Our lead product, ST-246�, is an orally administered antiviral drug that targets orthopox viruses. In December 2006 the FDA granted Orphan Drug designation to ST-246� for the prevention and treatment of smallpox. In May 2009, we submitted a response to a Request for Proposal (�RFP�) issued by BARDA with respect to the purchase of 1.7 million courses of a smallpox antiviral (the �BARDA Smallpox RFP�), and, in June 2009, BARDA informed us that our response to the BARDA Smallpox RFP was deemed technically acceptable and in the competitive range. There can be no assurance that SIGA or any other company will receive an award pursuant to this RFP.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    Item 1A. Risk Factors
    Item 1B. Unresolved Staff Comments
    PART I
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
        BALANCE SHEET
        Report of Independent Registered Public Accounting Firm
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers, and Corporate Governance
      Item 11. Executive Compensation
      Item 12. Security Ownership of Certain Beneficial Owners and ...
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accountant Fees and Services
    PART IV
      Item 15. Exhibits and Financial Statement Schedules
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 31.2
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS